AsclepiX Therapeutics Selected to Present at Ophthalmology Innovation Summit (OIS) at the American Society for Retinal Surgeons (ASRS) Annual Conference

Asclepix Therapeutics, Inc.
AsclepiX Therapeutics Selected to Present at Ophthalmology Innovation Summit (OIS) at the American Society for Retinal Surgeons (ASRS) Annual Conference
To Provide Update on AXT107 Duration of Efficacy Maintained for Over Thirteen Months to Date in Animal Models
AXT107 Inhibits VEGF and Activates Tie2 with Potential Once Yearly Dosing
July 16, 2019